



Life Long Learning

Trollway Anesthesia

New Anesthesia Drugs

Already here or on the Horizon



TOY
 Todd of Emerald is
 the only medical device
 designed for use in
 the operating room.
 It is a true
 medical device.

TOY
 Todd of Emerald is
 the only medical device
 designed for use in
 the operating room.
 It is a true
 medical device.

TOY
 Todd of Emerald is
 the only medical device
 designed for use in
 the operating room.
 It is a true
 medical device.

Tranquilizers <small>sedative</small>	Induction Agents <small>anesthetic</small>	Anticholinergic Agents <small>atropine</small>	Obstetrics <small>OB</small>
Tranq. Reversal <small>antidote</small>	Major Tranquilizers <small>sedative</small>		Hematological <small>OB</small>
Muscle Relaxants <small>paralytic</small>	Narc. / Tranq. Combos <small>anesthetic</small>	Antiemetics <small>anti-nausea</small>	Diuretics <small>OB</small>
Relevant Antagonists <small>antidote</small>	Vasopressors <small>pressor</small>	Antibiotics <small>antibiotic</small>	Radiology <small>OB</small>
Narcotics <small>anesthetic</small>	Hypotensive Agents <small>pressor</small>	Steroids <small>anti-inflammatory</small>	Misc. <small>OB</small>
Narcotic Antagonists <small>antidote</small>	Local Anesthetics <small>anesthetic</small>	Electrolytes <small>OB</small>	Invasive Line Tape <small>OB</small>

LTC Peter D. Strube

CRNA MSNA APNP ARNP DNAP(c)

Assistant Professor Rosalind Franklin University

Things are in evolution and only getting faster and faster!





Dedicated to:

Thomas G Healey, RN, CRNA, MA
St Mary's University
Died January 5, 2014

Navy Corpsman Vietnam





Financial Disclosure

There is no financial conflicts with this presentation.

Lecturing about a topic does not constitute endorsement of any product. Please take the time to research each topic for more information.

Mentioning a product or company does NOT represent endorsement.





Life Long Learning = Better Patient Care!

Trouble Before Anesthesia and Pharmacology



Mural of Dr. Villander, Hôtel de Dieu, Paris.

A



From *Behind the Doctor*, by Logan Clendenning, published by Alfred A. Knopf.

B



From *Devils, Drugs and Doctors*, by Howard W. Haggard, M.D., published by Harper and Brothers.

C

PICTORIAL RECORDS OF THE AGONY ENDURED IN OPERATIONS BEFORE THE ADVENT OF ANESTHESIA

- A. A surgeon cutting with his big saw.
- B. A very painful operation of the seventeenth century.
- C. A surgeon torturing his patient.



Life Long Learning = Better Patient Care!

Trollway & Anesthesia Crazy?



Exp: Lot:

04 B184 7/P5 (3377)

3 55292 10201 8

Desoxyn®
(methamphetamine hydrochloride tablets, USP)

5 mg Ⓢ only

DISPENSE THE ENCLOSED MEDICATION GUIDE WITH EACH PRESCRIPTION.
GO TO www.recordati-rarediseases.com

Each tablet contains 5 mg methamphetamine hydrochloride. See package insert for full prescribing information. Store below 86°F (30°C). Dispense in a USP light, light-resistant container. Do not accept if seal over bottle opening is broken or missing. Manufactured by: AbbVie LTD. For: Recordati Rare Diseases Inc. Lebanon, NJ 08833, U.S.A.







Think outside the BOX—
Think Differently!

Old Drugs, New Ways
New Drugs, Old Battles!

Pharmacogenetics----Micron Technology

Your DNA Affects Your Response to Drugs





We Must Start to Think

Differently!



Pediatric patients don't learn like we do?

What are the most abused Drugs in Peds?


FDA and Codeine?---- CPY2D6 ultra-rapid metabolizers

Codeine is a prodrug, meaning that it has to be converted into its active form, morphine, for its analgesic effect to be fully realized. Cytochrome P450 isoenzyme-2D6 (CYP2D6) is responsible for its hepatic conversion, and of course this extra biotransformation step increases the chances for alterations in the extent and speed of the enzyme's conversion of codeine to morphine.



Life Long Learning = Better Patient Care!

THINK OUTSIDE THE BOX



Think outside the BOX

We can no longer sit by the wayside, we must make ourselves better. Keep a OPEN Mind!

Multimodal

Synergy

Preemptive


Standard, Policy, Guideline, Suggestion???

Zofran



FDA Alerts!

FDA and Codeine?




U.S. Department of Health & Human Services

FDA U.S. Food and Drug Administration

What's New on the FDA Drugs Site

February 5, 2015

- [FDA's GDUFA Public Hearing on Policy Development](#)
- [Drug Firm Annual Registration Status \(updated\)](#)
- [Drug Firm Annual Registration Status Download File \(updated\)](#)
- [FDA Drug Shortages](#)
 - [Allogene Selfite Injection](#) (Updated - Currently in Shortage)
 - [Bupivacaine Hydrochloride \(Marcaine, Sensocaine\) Injection](#) (Updated - Currently in Shortage)
 - [Cefazolin Injection](#) (Updated - Currently in Shortage)
 - [Dextrose 5% Injection Bags](#) (Updated - Currently in Shortage)
 - [Dextrose Injection USP \(D5W\)](#) (Updated - Currently in Shortage)



these pediatric patients was comparable to the prevention of vomiting in patients 4 years of age and older.

Postoperative Nausea and Vomiting: Prevention of Postoperative Nausea and Vomiting:

Adult Studies: Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients. ZOFTRAN Injection (4 mg) IV, given over 2 to 5 minutes was significantly more effective than placebo. The results of these studies are summarized in Table 8.

Table 8. Prevention of Postoperative Nausea and Vomiting in Adult Patients

	Ondansetron 4 mg IV	Placebo	P Value
Study 1			
Emetic episodes:			
Number of patients	136	139	
Treatment response over 24-h postoperative period			
0 Emetic episodes	103 (76%)	64 (46%)	<0.001
1 Emetic episode	13 (10%)	17 (12%)	
More than 1 emetic episode/rescued	20 (15%)	58 (42%)	
Nausea assessments:			
Number of patients	134	136	
No nausea over 24-h postoperative period	56 (42%)	39 (29%)	
Study 2			
Emetic episodes:			



Tablets

Sprinkles

**Topamax®
(topiramate)**

NCBI Home Send to

Est. 2/19/2004 (vol 137) 476-7

High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre.

Boerka S*, Besser U, Ficht W, Schumacher S, Oelze K, Kroll G.

Author information

Abstract

The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open-label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months (P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment (P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti-migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well-tolerated alternative in migraine prophylaxis.

PMID: 1535748 (PubMed) indexed by MEDLINE



Publication Types, MeSH Terms, Substances

LinkOut - more resources

PubMed Commons

Full text links



Save items



Similar articles

- Botulinum toxin type A as migraine preventive treatment in patients previously [Headache. 2009]
- Prophylaxis of migraine, transformed migraine, and cluster headache with topa [Headache. 2002]
- Riboflavin prophylaxis in pediatric and adolescent migraine. [J Headache Pain. 2003]
- [Review] Supplementation with Riboflavin (Vitamin B2) for Migraine [Vitamins Nutr Res. 2013]
- [Review] Prophylactic treatments of migraine [Rev Neurol (Paris). 2000]

400 mg of riboflavin, 65 mg of caffeine and 325 mg Tylenol





Comfort Zone



Most of us practice our art in the comfort zone

New and different ideas tend to pull people from the comfort zone to the scare zone

Try new things

Enhance your patient outcomes





Wow.....



“You shouldn’t have that much pain?”

“Pain doesn’t raise your blood pressure”

“You should feel this way”

“This won’t be that painful”



“Do you have any pain?”

do you feel?”






Oxytocin is also thought to modulate inflammation by decreasing certain cytokines. Thus, the increased release in oxytocin following positive social interactions has the potential to improve wound healing.



Marazziti D, Dell'Osso B, Baroni S, Mungai F, Catena M, Rucci P, Albanese F, Giannaccini G, Betti L, Fabbrini L, Italiani P, Del Debbio A, Lucacchini A, Dell'Osso L (2006). "A relationship between oxytocin and anxiety of romantic attachment". Clinical Practice and Epidemiology in Mental Health **2** (1): 28. [doi:10.1186/1745-0179-2-28](https://doi.org/10.1186/1745-0179-2-28). [PMC 1621060](https://pubmed.ncbi.nlm.nih.gov/1621060/). [PMID 17034623](https://pubmed.ncbi.nlm.nih.gov/17034623/).





AFE – September 29, 2014 (presentation)

Dr. B Leighton, Cooper, Otto (abstract fall 2013)

41 G8P3-39 weeks at 31 min ACLS: Given A-OK at 1mg/8mg/30mg
Survived and left hospital with small neuro deficits

28 G2P1-39 weeks at ?? Min ACLS: Given A-OK at 0.8mg/4mg/30mg
Survived with no neuro issues

Thromboxane/serotonin

Use this in conjunction to current treatments.
At this time this is a adjunct to get the patient
to return to circulation.



Successful Management of Cardiac Arrest From Amniotic Fluid Embolism With Ondansetron, Metoclopramide, Atropine, and Ketorolac: A Case Report

Abstract Number: S 47

Abstract Type: Case Report/Case Series

Phillip L Copper MD¹; Maryann P Otto MD²; Barbara L Leighton MD³

Washington University in Saint Louis¹; Washington University in Saint Louis²; Washington University in Saint Louis³

Introduction: Amniotic fluid embolism (AFE), a rare obstetric event with high maternal and fetal mortality, consists of cardiac and pulmonary symptoms with consumptive coagulopathy. In animal models of pulmonary embolism, serotonin receptor blockers, cyclooxygenase inhibitors, and vagotomy improve cardiac function and decrease mortality.(1,2) Here we report a successful resuscitation of cardiac arrest from AFE using adult cardiac life support (ACLS) plus ondansetron, metoclopramide, atropine, and ketorolac.

Case: 41 yo G8P3043 woman presented at 39 weeks for labor induction. At complete cervical dilation, the patient complained of shortness of breath. Oxygen saturation decreased to 80% and within 1 minute she developed cardiac arrest. ACLS was initiated and the baby was quickly delivered via forceps. The patient was still pulseless after 40 minutes of ACLS. Atropine 1mg, ondansetron 8mg, metoclopramide 10mg, and ketorolac 30mg were then administered and the patient regained a pulse and stabilized within 2 minutes. A bedside echocardiogram one hour later showed a hyperdynamic left ventricle, a flat intraventricular septum, right ventricle pressure and volume overload, and preserved right ventricular function. Right heart failure improved quickly. The patient then developed consumptive coagulopathy. Profuse uterine bleeding requiring 13u PRBC, 6u FFP, 2u platelets, 30u cryoprecipitate, 2 doses of recombinant Factor VIIa, and an intrauterine Bakri balloon. She required hemodialysis for 5 days due to acute tubular necrosis. The patient developed speech and memory function difficulties which still persist. She was discharged to home on day 13.

Discussion: AFE treatment requires prompt resuscitative measures plus fetal delivery, yet maternal mortality is still high. Pulmonary hypertension and right-sided heart failure are seen with echocardiography in AFE cases.(3) Animal models suggest that significant embolism of any material is followed by platelet degranulation, pulmonary hypertension due to serotonin and thromboxane, and systemic hypotension due to vagal stimulation.(1,2) It was not until ondansetron (5-HT₃ antagonist), metoclopramide (5-HT₃ antagonist), atropine (vagolytic), and ketorolac (cyclooxygenase inhibitor) were given that the patient regained a pulse. It is likely that anti-serotonin, anti-thromboxane, and vagolytic therapy helped restore this patient's circulation and ultimately helped her survive AFE.

References:

1. Armstrong DJ, Miller SA. The role of platelets in the reflex tachypnoeic response to miliary pulmonary embolism in anaesthetized rabbits. *Exp Physiol* 1990;75:791-800.
2. Leanos OL, et al. Reflex circulatory collapse following intrapulmonary entrapment of activated platelets: Mediation via 5-HT₃ receptor stimulation. *Br J Pharmacol* 1995;116:2048-52.
3. James CF, et al. Massive amniotic fluid embolism: Diagnosis aided by emergency transesophageal echocardiography. *Int J Obstet Anesth* 2004;13:279-83.

SOAP 2013



AANA Journal June 2015

Role of Esmolol in Perioperative Analgesia and Anesthesia: A Literature Review

Megan Harless, CRNA, MSN

Caleb Depp, CRNA, MSN

Shawn Collins, CRNA, DNP, PhD

Ian Hewer, CRNA, MSN, MA

Use of opioids to provide adequate perioperative analgesia often leads to respiratory depression, nausea, vomiting, urinary retention, pruritus, and opioid-induced hyperalgesia, with the potential to increase length of stay in the hospital. In an effort to reduce perioperative opioid administration yet provide appropriate pain relief, researchers began to study the use of esmolol beyond its well-known cardiovascular effects. Perioperative esmolol has been shown to

reduce anesthetic requirements, decrease perioperative opioid use, decrease the incidence of postoperative nausea and vomiting, lead to an earlier discharge, and increase patient satisfaction. This article provides a review of the literature on the use of esmolol as an adjunct for perioperative analgesia and anesthesia.

Keywords: Esmolol, opioid sparing, perioperative analgesia and anesthesia.

perioperative pain with an opioid-sparing multimodal

Can you do a anesthetic without narcotics?





Not Everything is it appears? Labor Epidurals going away?

Blair et al Patient-controlled analgesia for labor using remifentanil: a feasibility study?

Remifentanil PCA with a bolus dose in the range 0.25–0.5 $\mu\text{g kg}$ and a lockout time of 2 min appears a safe and effective drug for use in labor in patient-controlled analgesia systems





Trolley Anesthesia Is Nitrous Back? 2009

The position of the American College of Nurse-Midwives that women should have access to a variety of measures to assist them in coping with the challenges of labor. Among these should be nitrous oxide, which is commonly used in many other countries.



Lowe, NK. The nature of labor pain. *Am J Obstet Gynecology* 2002;186(5):S16–24.

Marmor TR, Krol DM. Labor pain management in the United States: Understanding patterns and the issue of choice. *Am J Obstet Gynecology* 2002;186:S173–80.

Rooks JP. Nitrous oxide for pain in labor – why not in the United States? *Birth* 2007;34:3–.

Rosen MA. Nitrous oxide for relief of labor pain: A systematic review. *Am J Obstet Gynecology* 2002;186:S110–26

Declercq ER, Sakala C, Corry MP, Applebaum S. Listening to Mothers II: Report of the Second National U.S. Survey of Women's Childbearing Experiences. New York: Childbirth Connection, October 2006, p. 31.



Nitrous Oxide During Labor: Less Pain Relief, Better Patient Satisfaction

Share this content:



Despite lower reported effectiveness in labor pain, the degree of patient satisfaction in women who received nitrous oxide is similar to that of women who received neuraxial modalities, according to a study described in *Anesthesia & Analgesia*.¹

Although physicians in other countries have used nitrous oxide for decades to alleviate labor pain, this option has only recently been adopted in the United States. Previous research regarding its analgesic effectiveness has been largely inconclusive, and few studies have explored patient satisfaction associated with this modality.^{2,3} In the current investigation, researchers at Vanderbilt University Medical Center in Nashville, Tennessee, retrospectively examined data collected since their facility began offering self-administered nitrous oxide as an analgesic option in 2011.



Nitrous oxide has only recently been adopted in the United States to alleviate labor pain.

2002; 186(5 Suppl Nature): S110-23.

1. Likis FE, Andrews JC, Collins MR, et al. Nitrous oxide for the management of labor pain: a systematic review. *Anesth Analg*. 2014; 118(1):153-67. doi: 10.1213/ANE.0b013e3182a7f73c
2. Hodnett ED. Pain and women's satisfaction with the experience of childbirth: a systematic review. *Am J Obstet Gynecol*. 2002; 186(5 Suppl Nature): S160-72.



Trollway Anesthesia Tranexamic Acid

New to Ortho World

A competitive inhibitor of plasminogen, and in high concentrations a non-competitive inhibitor of plasmin

Less transfusions -- reported 50%

Trauma: Antifibrinolytic agent

Increased trauma survival in prospective analysis

Can't have blood products, Hextend in same line

Give within 3 hours- 1gm in 100mL NS over 10 mins

Then start infusion of 1gm in 100mL NS over 8 hours


Pump rate 12.5ml/hr

Further doses can be given, though not supported by literature

Joints... dosing all over the place

Spine surgery, 10 mg/kg up to 1000mg load followed

By 1 mg/kg/hr. infusion for duration of case



Certified Registered Nurse Anesthetist


Anesth Analg. 2005; Nov;101(5):1516-20.

Piccini VA, et al. Tracheal intubation and dexmedetomidine in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study.

Anesthesiology, 2015; 15(18)



Trolleyway Anesthesia



30 minutes before injecting narcotic spinal or epidural






New MH Drug? Ryanodex

The drug, an injectable suspension of dantrolene sodium, will be available in 250 mg single-use vials containing the active ingredient in a lyophilized powder.

According to Eagle Pharmaceuticals, Ryanodex can be prepared and administered in less than one minute, compared with 15 to 20 minutes for conventional dantrolene.



The cost for a patient receiving Ryandex treatment for a MH crisis (based off 2.5mg/kg in a 70kg patient) is \$1,610 verses \$700 with generic dantrolene. This cost does not include additional doses of dantrolene that will be required

This research and orphan drug status is leading to additional research... for example for heat stroke:





Fospropofol (Lusedra)

Approved by the FDA on 12/12/08 as a pro-drug of propofol

Same mechanism of action; except has a slow, smooth and predictable rise in concentration

By; Definition: this is a sedative-hypnotic aqueous agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.

NOT FOR GENERAL




This will and has already raised some concern—FDA states that only those trained in delivering anesthesia should use this drug. What about the ago old question??

What about using this in GI clinic





Trollway & Anesthesia Fospropofol (Lusedra)





Clinical Therapeutics/Volume 38, Number 1, 2016

Magnesium Sulfate Plus Lidocaine Reduces Propofol Injection Pain: A Double-blind, Randomized Study

Jiehao Sun, MD; Riyong Zhou, MD; Wendong Lin, MD; Jiahao Zhou, MD; and Weijan Wang, MD

Department of Anesthesiology, 1st Affiliated Hospital, Wenzhou Medical University, Wenzhou, China

ABSTRACT

Purpose: Propofol injection can cause distressing pain, and no method can inhibit it completely. Neither lidocaine nor magnesium sulfate ($MgSO_4$) was sufficient to prevent pain from the injection of propofol. This prospective, double-blind, placebo-controlled study was designed to investigate the efficacy of the $MgSO_4$ plus lidocaine on suppressing propofol injection pain.

Methods: Three hundred women received 300 mg $MgSO_4$ (Group M), 40 mg lidocaine (Group L), or 300 mg $MgSO_4$ plus 40 mg lidocaine (Group M+L). This was followed by administration of 50 mg propofol. Pain scores, behavior-related responses, and diameter of the vein were recorded following the injection of propofol.

Findings: Patients in Group M + L had lower pain scores. Patients' behavior-related responses in Group M + L were also better compared with the other groups. There were no differences in pain scores

priority for improvement.¹ Minimizing propofol injection pain is an important clinical goal because it may influence a patient's perception of quality and acceptability of anesthesia. Several measures have been used to reduce the occurrence of propofol injection pain, including the addition of lidocaine with tourniquet; cooling or warming the propofol; diluting the propofol solution; injection of propofol into a large vein; or prior injections of meperidine, metoclopramide, magnesium, thiopental, ketamine, methylene blue, or a β -blocker.¹⁻⁷ We have not found a method that suppresses injection pain completely.

Tourniquet causes dilation of veins, and, interestingly, vein size is an important factor in propofol injection pain.⁸ A meta-analysis¹ suggested that use of a rubber tourniquet and lidocaine application before propofol injection was most effective to prevent injection pain. Dae et al⁹ demonstrated that higher doses of lidocaine can achieve more analgesia, but the incidence of pain can be still as high as 36.8% when a



The Use of Magnesium Sulfate to Prevent Pain on Injection of Propofol

Dilek Memiş*, Alparslan Turan*, Beyhan Karamanlıoğlu*, Necdet Süt†, and Zafer Pamukçu*

Departments of *Anesthesiology and †Biostatistics, Trakya University Medical Faculty, Edirne, Turkey

[Journal Anesthesis](#)
April 2015, Volume 20, [Issue 1](#), pp 206-211

Magnesium sulfate with lidocaine for preventing propofol injection pain: a randomized, double-blind, placebo-controlled trial

Authors [Address and affiliations](#)

Bihun F. (alpar) [DOI](#), Peter S. (suta), İsmail H. (karamanlioglu), S. (necdet), E. (pamukcu), S. (memis)

Original Article

First published online 2015

DOI: 10.1007/s00249-014-1092-9

Cite this article as:

MEMİŞ D, TURAN A, KARAMANLIOĞLU B, SÜT N, PAMUKÇU Z

ANESTHESIS 2015; 20(1): 206-211

[http://dx.doi.org/10.1007/s00249-014-1092-9](#)



Citations Share Download

Vein pretreatment with magnesium sulfate to prevent pain on injection of propofol is not justified

[Un prétraitement veineux au sulfate de magnésium n'est pas justifié pour prévenir la douleur causée par l'injection de propofol]

Anil Agarwal MD,* Sanjay Dhiraj MD,* Mehdi Raza MD,* Ravinder Pandey MD,* Chandra Kant Pandey MD,* Prabhat K. Singh MD,* Uttam Singh PhD,† Devendra Gupta MD*



Remimazolam

- Analogue of Midazolam
 - ▶ that utilizes the ester design.
 - ▶ Broken down by nonspecific ester hydrolysis
- Designed for out patient procedures as well as EGD/C-Scope area
- Linear Clearance superior to Versed
- Better sedation with less side effects of Versed
 - respiratory and cardiac events
- **6mg loading Dose followed by 3 mg maintenance doses**
- Crazy but initial studies have not change in ventilation or oxygenation with remidmazolam with NO supplemental oxygen applied.....

Product Profiles	Remimazolam	Propofol	Sevoflurane
Rapid time to peak effect	✓	✓	✓
Rapid offset	✓	✓	✓
Predictable recovery time	✓	✓	✓
Early discharge	✓	✓	✓
Low respiratory depression	✓	✗	✗
Cardiostability	✓	✗	✗
Early recovery to full cognition	✓	✗	✗
Reversal agent available	✓	✗	✗
Low re-sedation risk after reversal	✓	-	-
No (low) pain on injection	✓	✗	-
Low risk of excitation ¹	✓	✓	✗
No risk of theatre contamination	✓	✓	✗
No risk of atmospheric pollution	✓	✓	✗
Simple equipment to handle	✓	✓	✗

¹Using indicator of record





Paion Presents Positive Remimazolam Phase III Colonoscopy Results at the 2016 American College of Gastroenterology Annual Scientific Meeting

← 3 Pharmaceutical Stocks t

I low ml health Will Change t →

Chelsea Fratt • October 19, 2016

[Add Comment](#)



PAION AG, a specialty pharma company (ISIN DE000A0B6563; Frankfurt Stock Exchange Prime Standard: PA8) today announces that data on the clinical results of remimazolam's U.S. Phase III colonoscopy trial were presented in the Colon/Stomach oral session at the 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas. Remimazolam is an innovative, ultra-short-acting benzodiazepine anesthetic/sedative for which positive topline data from this trial were published in June 2016.

Douglas Rex, M.D., Indiana University, Indianapolis, IN, U.S., principal investigator of this Phase III trial, presented the results.

The Phase III trial enrolled a total of 461 patients at 13 U.S. sites.

^ Rogers WK, McDowell TS (December 2010). "Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day case surgical and non surgical procedures". *Drugs : the Investigational Drugs Journal* 13 (12) 929-37. PMID 21154153



**ified
Registered
Nurse
Anesthetist**




Trollway Anesthesia

Etomidate -- MOC


Methoxycarbonyl-etomidate (MOC-etomidate), a new compound derived from the anesthetic etomidate, is as fast-acting and provides the same hemodynamic stability as its parent drug, but does not cause dangerous adrenal gland suppression as etomidate can

In the human liver cells, the researchers found that the MOC-etomidate had an in-vitro half-life of 4.4 minutes versus more than 40 minutes for etomidate, and produced carboxylic acid as its only detectable metabolite


MOC-etomidate is an etomidate analogue that retains etomidate's important favorable pharmacological properties. However, it is rapidly metabolized, ultra-short acting, and does not produce prolonged adrenocortical suppression following bolus administration



Etomidate



MOC-etomidate



Carboetomidate

[Curr Pharm. Des.](#)
2012;18(38):6253-6.

**Novel etomidate
dérivatives.**

[Sneyd DR¹.](#)



Carboetomidate

- Analogue of etomidate
- When compared to MOC it has slow onset and difficult to formulate.
- ??? Benefit ???



Phaxan

Water-based clear, colorless solution that is easy to manufacture.

Like propofol, the current standard for intravenous anesthesia, Phaxan™ is a fast onset and offset intravenous anesthetic but, unlike propofol, there is no accumulation with repeat dosing.

Phaxan™ is twice as potent as propofol but it causes less blood pressure fall than propofol with a six times higher safety margin.

A clinical trial involving dose finding and comparison with propofol was commenced in December 2013.

Interesting thought... old stuff coming back??





The screenshot shows a web browser window displaying the website for Drawbridge Pharmaceuticals. The address bar shows the URL drawbridgepharmaceuticals.com.au/phaxan-intravenous. The website header includes a search bar, the email address info@drawbridgepharmaceuticals.com.au, and a navigation menu with links for home, publications, our team, products, news, and partnering. The main content area features the Drawbridge Pharmaceuticals logo and a section titled "Phaxan™: Intravenous Anaesthetic and Sedative".

Phaxan™: Intravenous Anaesthetic and Sedative

Phaxan™ is an intravenous general anaesthetic and sedative containing alphaxalone as the active pharmaceutical ingredient. Alphaxalone is a neuroactive steroid anaesthetic, it is a pregnanecone with no endocrine/hormonal activity. This water-insoluble drug was initially formulated using CremophorEL and marketed as Althesin® from 1971 to 1984. It was found to be a safe and versatile intravenous anaesthetic used in clinical practice in anaesthesia and intensive care in many countries until it was withdrawn from clinical practice because of hypersensitivity to the CremophorEL.

Many subsequent attempts to make an aqueous formulation of neuroactive steroids suitable for human use have failed. Drawbridge Pharmaceuticals' proprietary and patented formulation, Phaxan™, is a solution of alphaxalone 10mg/ml dissolved in 13% SBECED (7- sulfabutylether β-cyclodextrin); a molecule with a lipophilic cavity that enables drug dispersal in water for human use. The use of SBECED as the excipient preserves all of the advantages and utility of alphaxalone so evident when it was formulated as Althesin® but now avoiding all of the problems caused by the CremophorEL. The properties of the new anaesthetic preparation:



Trollway & Anesthesia Dexamethasone



- Steroids are useful as adjuvant therapy for pain
- Steroids can directly reduce pain in concert with opioid use and allow for a reduction in dose
- Steroids reduce pain by inhibiting prostaglandin synthesis
- Steroids have been shown to reduce spontaneous discharge in an injured nerve, which reduces neuropathic pain.
- **What if we could add it to our Blocks? Increase our Duration!**





De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ

- Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials
- Doses of 0.1 mg/kg or less are great for PONV but don't help with pain relief.
- **Doses of about 0.15 mg/kg cover PONV and reduce postoperative pain and opioid demand. 100kg patient should be getting 15 mg**
- Doses above 0.2 mg/kg don't get you any more pain relief. An exception may be greater pain relief with movement (e.g. early ambulation in total joint patients?).
- Giving dexamethasone *preoperatively* improves pain relief considerably more than giving it after induction. (Optimally 1-2 hours before incision.)
- In general, we need not worry about side effects with 0.15 mg/kg any more than we do with current PONV doses.



Effect of dexamethasone on the duration of interscalene nerve blocks with ropivacaine or bupivacaine

K. C. Cummings III^{1,2*}, D. E. Napierkowski⁴, I. Parra-Sanchez², A. Kurz², J. E. Dalton^{2,3}, J. J. Brems⁵
and D. I. Sessler²

¹Department of Regional Practice Anesthesiology, Cleveland Clinic, Lakewood Hospital Department of Anesthesiology, 14519 Detroit Avenue, Lakewood, OH 44107, USA

²Department of Outcomes Research and ³Department of Quantitative Health Sciences, Cleveland Clinic, 9500 Euclid Avenue—P77, Cleveland, OH 44195, USA

⁴Department of Regional Practice Anesthesiology and ⁵Department of Orthopaedic Surgery, Cleveland Clinic, Euclid Hospital, 18901 Lake Shore Blvd, Euclid, OH 44119, USA

* Corresponding author: 9500 Euclid Ave, Mailcode E30, Cleveland, OH 44195, USA. E-mail: cummink2@ccf.org

Editor's key points

- This trial demonstrates a difference in block

Background. Pain after shoulder surgery is often treated with interscalene nerve blocks. Single-injection blocks are effective, but time-limited. Adjuncts such as dexamethasone may help. We thus tested the hypothesis that adding dexamethasone significantly prolongs the duration of ropivacaine and bupivacaine analgesia and that the magnitude

Dexamethasone with bupivacaine increases duration of analgesia in ultrasound-guided interscalene brachial plexus blockade

Peter A. Vieira, Istvan Pulai, George C. Tsao, Poornachandran Manikantan, Brunella Keller and Neil Roy Connely

Background and objective Dexamethasone has been shown to prolong the duration of postoperative analgesia when given as an adjunct for peripheral nerve blocks. However, it has not been evaluated when given in conjunction with bupivacaine and clonidine to provide blockade of the brachial plexus at the interscalene level. The purpose of this investigation was to determine whether the addition of dexamethasone to interscalene brachial plexus block would prolong the duration of sensory analgesia in a group of patients undergoing outpatient shoulder arthroscopy.

Methods This prospective, randomized, double-blind investigation was performed on 60 individuals undergoing shoulder arthroscopy. Patients received interscalene brachial plexus block using 20 ml of bupivacaine 5 mg ml⁻¹ with 1:500,000 epinephrine and clonidine 75 µg. Patients were randomly assigned to receive either dexamethasone 8 mg or 0.9% NaCl as an adjunct to the mixture. After discharge, patients received pain scores and analgesic consumption in a diary and estimated the time at which they perceived that the sensory block from the interscalene brachial plexus block resolved. This was based on pain, recovery of sensation and strength in the arm. Variables measured included demographics,

limb pain intensity measurements, postoperative analgesic consumption, duration of analgesia and patient satisfaction.

Results Dexamethasone prolonged median sensory (1457 vs. 893 min, $P < 0.0001$) and motor (1374 vs. 827 min, $P < 0.0001$) blockade compared with the control. At 24 h, the dexamethasone group had lower median verbal analogue scale scores compared with control (8.0 vs. 6.0). At 48 h, the two groups had similar median pain scores (4.0 vs. 5.0, dexamethasone vs. control, respectively). The opioid requirement in oxycodone equivalency was lower in the dexamethasone group than in the control group for the first 24 h, and similar thereafter. Median patient satisfaction scores were not significantly different between the two groups at 48 h (5.0 vs. 5.0, dexamethasone vs. control, respectively).

Conclusion The addition of dexamethasone to a bupivacaine-epinephrine-clonidine interscalene block prolongs sensory block and reduces opioid use.

Eur J Anaesthesiol 2010;27:285–288

Keywords: arthroscopy, anaesthesia, analgesia, brachial plexus, clonidine, dexamethasone, regional

Received 7 June 2009; Revised 2 November 2009; Accepted 8 November 2009

Introduction

Regional anaesthesia has gained much popularity in outpatient orthopaedic surgery. Increasing duration of limb

addition of epinephrine prolongs duration of subcutaneous infiltration of local anaesthesia.²





It is OK.....

The Effect of Single Low-Dose Dexamethasone on Blood Glucose Concentrations in the Perioperative Period: A Randomized, Placebo-Controlled Investigation In Gynecologic Surgical Patients

Murphy, Glenn S. MD^{*}, Szokol, Joseph W. MD^{*}, Avram, Michael J. PhD^{*}, Greenberg, Steven B. MD^{*}, Shear, Torin MD^{*}, Vender, Jeffrey S. MD^{*}, Gray, Jayla BA^{*}, Landry, Elizabeth BA^{*}

Anesthesia & Analgesia
June 2014, Volume 118, Issue 6, p 1204-1212
doi: 10.1213/ANE.0b013e31828539d1
Ambulatory Anesthesiology: Research Report



**Certified
Registered
Nurse
Anesthetist**



Emend (Aprepitant) PDNV



- A new class of antiemetic's is born -- NK-1 receptor antagonists
- Does not interfere with other antiemetic's
- No dosage adjustments for hepatic or renal compromise
- Does not effect QT segments
- Use in caution with CYP3A4 (warfarin) drugs; this is typically related to a three day course in chemo-related treatments
- Decreases efficacy of hormonal contraceptives
- Anesthesia is a single dose; 40-80mgs
- Expensive single 80mg dose is \$125





Emend (Aprepitant)

- This is a additional adjunct treatment to those refractory to PONV
- Most side effects are related to prolonged and high doses with little evidence that any effects are related to a single anesthesia dose
- Top adverse experiences in patients with general anesthesia were;
 - Anemia, bradycardia, flatulence, hypotension, pruritus, pyrexia
- Expensive ; Expensive; Expensive; Expensive
- Two additional NK-1 Drugs: Casopitant, Rolapitant





Rolapitant

VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting.

The recommended dosage is 180 mg Rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy

Administer in combination with dexamethasone and a 5-HT3 receptor antagonist,

TESARO In-licensed to: Dec. 2010;
2009 FTC **OPKO** ordered it
divested from
"the bust-up": Schering-Plough...
now branded as... **VARUBI**

FDA Approved
1/11/07 27015

Rolapitant HCl
 $C_{25}H_{29}ClF_6N_2O_3$

...now, a competitor to:

EMEND[®]
(aprepitant)

MERCK



Akynzeo

Akynzeo, a combination product of netupitant and palonosetron

Each capsule contains 300 mg of netupitant, and palonosetron hydrochloride equivalent.

1 Capsule

NDC 62856-796-01
Rx Only

Akynzeo[®]
(netupitant and palonosetron)
capsules, 300mg/0.5mg

Each capsule contains 300 mg netupitant and
0.56 mg palonosetron hydrochloride equivalent to
0.50 mg palonosetron free base



Jointly manufactured by Catalent Pharma Solutions, Somerset, NJ
and Helsinn Biex Pharmaceuticals Ltd, Dublin, Ireland.



**Nurse
Anesthetist**



Trolley Anesthesia Oxygen

Hypoxia triggers cortical afferents which triggers the vomiting center which leads to the act of vomiting

Enhanced Rec | brydger press | Enhanced Rec | Fluid Manager | FluidMgmt.pdf | Eras | Inhance | Enhanced Rec | ppt Perioperati | Effect of in x

ncbi.nlm.nih.gov/pubmed/23719611

Advanced

Format: Abstract - Send to -

Anesthesiology, 2013 Aug;119(2):393-16. doi: 10.1097/ALN.0b013e31829aaff4

Effect of intraoperative high inspired oxygen fraction on surgical site infection, postoperative nausea and vomiting, and pulmonary function: systematic review and meta-analysis of randomized controlled trials.

Hosokawa E*, Lyszkowski D, Eban T, Trancl M

Author information

Abstract

BACKGROUND: Intraoperative high inspired oxygen fraction (FIO2) is thought to reduce the incidence of surgical site infection (SSI) and postoperative nausea and vomiting, and to promote postoperative atelectasis.

METHODS: The authors searched for randomized trials (18 September 2012) comparing intraoperative high with normal FIO2 in adults undergoing surgery with general anesthesia and reporting on SSI, nausea or vomiting, or pulmonary outcomes.

RESULTS: The authors included 22 trials (7,001 patients) published in 26 reports. High FIO2 ranged from 50 to 100% (median, 80%); normal FIO2 ranged from 30 to 40% (median, 30%). In nine trials (5,103 patients, most received prophylactic antibiotics), the incidence of SSI decreased from 14.1% with normal FIO2 to 11.4% with high FIO2; risk ratio, 0.77 (95% CI, 0.59-1.00). After colorectal surgery, the incidence of SSI decreased from 19.3 to 15.2%; risk ratio, 0.78 (95% CI, 0.68-1.02). In 11 trials (2,263 patients), the incidence of nausea decreased from 24.8% with normal FIO2 to 19.4% with high FIO2; risk ratio, 0.79 (95% CI, 0.66-0.93). In patients receiving inhalational anesthetics without prophylactic antiemetics, high FIO2 provided a significant protective effect against both nausea and vomiting. Nine trials (3,698 patients) reported on pulmonary outcomes. The risk of atelectasis was not increased with high FIO2.

CONCLUSIONS: Intraoperative high FIO2 further decreases the risk of SSI in surgical patients receiving prophylactic antibiotics, has a weak beneficial effect on nausea, and does not increase the risk of postoperative atelectasis.

Comment in

Benefits and risks of intraoperative high inspired oxygen therapy. Firm conclusions are still far off. [Anesthesiology, 2014]

Does high oxygen concentration reduce postoperative infection? [Anesthesiology, 2014]

In reply. [Anesthesiology, 2014]

Intraoperative high inspired oxygen fraction: are there real benefits? [Anesthesiology, 2014]

PMID: 23719611 DOI: 10.1097/ALN.0b013e31829aaff4

[PubMed - indexed for MEDLINE]

Full text links

ANESTHESIOLOGY

Save items

Add to Favorites

Similar articles

Intraoperative high inspired oxygen fraction: are there real benefits? [Anesthesiology, 2014]

Surgical site infection and the routine use of perioperative hyperoxia in a general [JAMA, 2004]

Benefits and risks of intraoperative high inspired oxygen therapy: firm conclusions [Anesthesiology, 2014]

Review [Supplemental oxygen for the prevention of postoperative [Rev Esp Anestol Reanim, 2008]

Review Effect of intra-operative high inspired oxygen fraction on surgical [J Hosp Infect, 2016]

See reviews...

See all...

Cited by 12 PubMed Central articles

Review Integrated approach to colorectal anastomotic leakage [World J Gastroenterol, 2016]

Cardiac surgery: a right target for hyperoxia? [Crit Care, 2016]

Electrical Impedance Tomography-guided PEEP




Perioperative clinical factors & immune function

Supplemental perioperative oxygen improves postop outcomes

FO₂ of 0.8 doubles subcut O₂ tension & halves postop wound infection rate

Supplemental O₂ ↓ PONV after laparoscopies & laparotomies






Trollway Anesthesia Cannabinoids



- Salivex
- Ajulemic acid
- Nabilone
- Marinol
- Cannadur
- Cannabis



As of 2013; 23 controlled studies looking at Cannabinoids for pain management



MARINOL should not be used if you are

- allergic to dronabinol or any of its ingredients,
 - including marijuana and sesame oil
- Most patients respond to 5 mg three or four times daily.
- Marinol has been shown to provide increased pain relief when taken in combination with opioid pain relievers, according to ClinicalTrials.gov. The active ingredient in Marinol, THC, is believed to bind with pain receptors to reduce the transmission of pain through the spinal cord and brain

THIS STUDY HAS BEEN COMPLETED.

Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development

ClinicalTrials.gov Identifier:
NCT02957822
First received: September 19, 2004
Last updated: April 7, 2016
Last verified: April 2016
[History of Changes](#)

[Full Text View](#) | [Tabular View](#) | [Study Results](#) | [Disclaimers](#) | [How to Read a Study Protocol](#)

Purpose

This study will compare two different drug regimens that do not contain opioids in a double-blind, randomized, controlled trial for the prevention of post-operative nausea and vomiting (PONV).

Condition	Intervention
Postoperative Nausea and Vomiting	Drug: Ondansetron Drug: Propofol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind (Participant, Caregiver, Investigator)
Primary Purpose: Treatment

Official Title: Prevention of Postoperative Nausea and Vomiting in Surgical Patients

Resources provided by NLM:

[MedlinePlus related topics: Nausea and Vomiting](#)

Advanced Search

NCE is currently redirecting web traffic to HTTPS. Read more about our https switch.

Format: Abstract | Send to: | Full text links | Save items | Similar articles

Prevention of nausea and vomiting following breast surgery. [Full text links](#)

Livstone E, Sivole K, Kasi B, Hemo-Tilhan R, Cabral J, Sanders S, Kimble VS

Author information

Abstract

BACKGROUND: The purpose of this study was to determine the rates of nausea and vomiting in women following breast surgery (PONV) under general anesthesia (GA), before and after the introduction of a standard prophylactic anti-emetic (AC) regimen.

METHODS: One thousand a retrospective review of veteran patients, between July 2007 and March 2014. Patients operated on before September 2007 had standard prophylactic care (not AC), patients operated on after September 2007 were treated prophylactically with oral ondansetron 8mg and intravenous prochlorperazine 12mg linear (oral) (OC). Data were collected from hospital records regarding age, diabetes, cardiac conditions, previous anesthesia history, anesthesia and operative details, episodes of PONV, and use of AC. The rate and severity of PONV was calculated for both cohorts.

RESULTS: Two thousand thirty-two patients were treated: 127 patients in the OC and 115 patients in the AC. The median age was 64 years (range 33 to 89). The rate of nausea and vomiting were significantly lower in the OC group in the linear (OC) group (15% vs. 25%, P = .008 and 20% vs. 30%, P = .001). Twenty patients in the OC were given some prophylactic AC treatment and 12 (60%) of them required further treatment, only 12 of 103 patients (11%) in the AC required further AC treatment (P = .008).

CONCLUSION: PONV is a significant problem in breast surgical patients. Preoperative treatment with ondansetron and prochlorperazine significantly reduced the incidence and severity of episodes of PONV.

PMID: 25221494 DOI: 10.1186/s12874-015-0190-0



2012

Browser tabs: (11 unread) - pstrube, My eBay Summary, kelet h, dahl jb, ane, Society Blog View | A, A 'civil war' over pain, graise - Bing, Russo-Hohmann

Address bar: theroc.us/images/Russo-Hohmann%20Role%20of%20cannabinoids%20in%20pain%20management%20from%20Deer%202013.pdf

Role of Cannabinoids in Pain Management

Ethan B. Russo and Andrea G. Hohmann

18

Key Points

- Cannabinoids are pharmacological agents of endogenous (endocannabinoids), botanical (phytocannabinoids), or synthetic origin.
- Cannabinoids alleviate pain through a variety of receptor and non-receptor mechanisms including direct analgesic and anti-inflammatory effects, modulatory actions on neurotransmitters, and interactions with endogenous and administered opioids.
- Cannabinoid agents are currently available in various countries for pain treatment, and even cannabinoids of botanical origin may be approved by FDA, although this is distinctly unlikely for smoked cannabis.
- An impressive body of literature supports cannabinoid analgesia, and recently, this has been supplemented by an increasing number of phase I-III clinical trials.

and their role in inflammation. The opium poppy (*Papaver somniferum*) provided the prototypic narcotic analgesic morphine, the first alkaloid discovered, and stimulated the much later discovery of the endorphin and enkephalin systems. Similarly, the pharmacological properties of cannabis (*Cannabis sativa*) prompted the isolation of Δ^9 -tetrahydrocannabinol (THC), the major psychoactive ingredient in cannabis, in 1964 [2]. It is this breakthrough that subsequently prompted the more recent discovery of the body's own cannabis-like system, the endocannabinoid system (ECS), which modulates pain under physiological conditions. Pro-nociceptive mechanisms of the endocannabinoid system were similarly revealed by phytochemistry of capsaicin, the pungent ingredient in hot chile peppers (*Capiscum annuum* etc.), which activates transient receptor potential vanilloid receptor-1 (TRPV1). Additional plant products such as the mints and mustard activate other TRP channels to produce their physiological effects.

The Endocannabinoid System

11:21 AM 2/17/2017



Olanzapine as an antiemetic:
is an atypical antipsychotic that belongs to the thienobenzodiazepine class.

Olanzapine cost:

- Rapidly disintegrating tab 5mg: ~ \$1.00
- Rapidly disintegrating tab 10mg: ~ \$1.15
- Tab 5mg: \$0.10
- Tab 10mg: \$0.20
- IM injection: \$25.25



We only have a very small amount of information about the use of olanzapine IV, and none of it in the periop period.....

Most Studies looked at it as compared to Zofran.....






Treatment of Postoperative Nausea and Vomiting (PONV)

PDNV



- A new 5HT-3 receptor antagonist
- Aloxi binds with both the serotonin site but also a allosteric binding site; this action increases the overall affinity for aloxi by triggering a **conformational change**. This change also causes a receptor internalization and induces a prolonged inhibition of serotonin binding to the cell surface receptors.
- What is cool about it?? 40 hour plasma half-life
- Small single dose --- 0.075 mg single dose
- Easy to remember dose timing -- before induction of anesthesia in preop over 10 seconds
- NO information for Peds or OB



these pediatric patients was comparable to the prevention of vomiting in patients 4 years of age and older.

Postoperative Nausea and Vomiting: Prevention of Postoperative Nausea and Vomiting:

Adult Studies: Adult surgical patients who received ondansetron immediately before the induction of general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) were evaluated in two double-blind US studies involving 554 patients. ZOFTRAN Injection (4 mg) IV, given over 2 to 5 minutes was significantly more effective than placebo. The results of these studies are summarized in Table 8.

Table 8. Prevention of Postoperative Nausea and Vomiting in Adult Patients

	Ondansetron 4 mg IV	Placebo	P Value
Study 1			
Emetic episodes:			
Number of patients	136	139	
Treatment response over 24-h postoperative period			
0 Emetic episodes	103 (76%)	64 (46%)	<0.001
1 Emetic episode	13 (10%)	17 (12%)	
More than 1 emetic episode/rescued	20 (15%)	58 (42%)	
Nausea assessments:			
Number of patients	134	136	
No nausea over 24-h postoperative period	56 (42%)	39 (29%)	
Study 2			
Emetic episodes:			



Anesthesia and Analgesia 2016; 122:656

Meta-Analysis of studies from 1974-2014

Drastically reduced PONV, especially with preop and small dose 30 minutes before extubation.



Clinical Research Article

Korean J Anesthesiol 2012 April 62(4): 343-349
<http://dx.doi.org/10.4097/kjae.2012.62.343>

The antiemetic effect of midazolam or/and ondansetron added to intravenous patient controlled analgesia in patients of pelviscopic surgery

Dae Seong Kim, Gil Hoi Koo, Hyun Kang, Chong Wha Baek, Yong Hun Jung, Young Cheol Woo, Jin Yun Kim, and Sun Gyo Park

Department of Anesthesiology and Pain Medicine, College of Medicine, Chung-Ang University, Seoul, Korea

Background: We made a comparative study on the antiemetic effect of midazolam and ondansetron added to intravenous patient-controlled analgesia (PCA) using fentanyl with gynecologic patients undergoing pelviscopic surgery.

Methods: The PCA using 20 µg/kg of fentanyl was started in all groups postoperatively. A dose of 16 mg of ondansetron was added to the PCA of group O (n = 30). A dose of 5 mg of midazolam was added to the PCA of group M (n = 30). While 16 mg of ondansetron and 5 mg of midazolam were added to the PCA of group MO (n = 30). Total volume of the PCA was 60 ml, and the PCA system was programmed to deliver 0.5 ml/h of continuous doses and a 0.5 ml bolus on demand, with a 15 minutes lockout interval. The incidence of postoperative nausea and vomiting (PONV), sedation score, visual analog scale (VAS) for pain, and rescue drug dose for PONV were investigated at the postanesthesia care unit (PACU), 6 hours, and 24 hours after recovery.

Results: The incidence of PONV in group MO was significantly lower than in group O at PACU, 24 hours after recovery ($P < 0.05$). The sedation score and VAS pain score showed no differences among all groups.



The last 30 minutes Versed

Lee Y, Wang JJ, Yang YL, Chen A, Lai HY. Midazolam vs ondansetron for preventing postoperative nausea and vomiting: a randomized controlled trial. *Anaesthesia*. 2007;62(1):18-22.



Non-Pharmacologic Methods for PONV



- Acupuncture—really exciting information!
- Acupressure
 - over “P6” point of wrist (3cm prox. to distal wrist crease, between the tendons of palmaris longus and flexor carpi radialis)
 - over K-K9 acupuncture point (middle phalanx of 4th finger) applied bilaterally
- Alcohol Pad—Quese Ease!



September 2013; Anesthesia and Analgesia: Aromatherapy as Treatment for Postoperative Nausea: A Randomized Trial
Hunt, Ronald MD*; Dienemann, Jacqueline PhD, RN[†]; Norton, H. James PhD[‡]; Hartley, Wendy MSN, RN[§]; Hudgens, Amanda BSN, RN^{||}; Stern, Thomas MD[¶]; Divine, George PhD[#]





Blood Pressure

The BEST treatment of choice for beta-blocker overdose is?

- A. Glucagon
- B. Methylene Blue
- C. Esmolol
- D. Vasopressin



- Glucagon enhances the formation of cAMP.
- Glucagon is used to increase myocardial contractility and heart rate in the setting of beta-blocker toxicity.
- Glucagon stimulates catecholamine release and has been used as a diagnostic tool in pheochromocytoma.
- Dose:
 - 1-5 mg IV slowly
 - Infusion: 25–75 mcg/min




Glucagon must be reconstituted immediately prior to administration.



Hypotensive Thought Pattern

- What is your order for treating Hypotension????
- 0 fluids
- 1 and 2; Neo and ephedrine
- 3 methylene blue
- 4 epi chip shots (5-10mcg)—Guy Weinbe
- 5 vasopressin
- What is 6 for you?
- ?? Glucagon





Trolley Anesthesia Hemodynamic Effects of

Methylene Blue

Methylene blue, a commonly used tissue marker is normally hemodynamically inert.

However, for a variety of clinical scenarios associated with an inflammatory response, methylene blue results in increases of systemic blood pressure, systemic vascular resistance (SVR), and myocardial contractility.

The application of methylene blue's effects is also being studied in the management of numerous clinical scenarios, including:

- vasoplegia
- anaphylactic shock
- septic shock
- hypotension from ACE-Is/ARBs
- hemodialysis hypotension
- cardiogenic shock





Dosing of Vasopressin


Intraoperative hypotension

- Dilute with 19 mL NS in a 20 cc syringe to create a concentration of 1 unit/mL.
- Administer 0.5 – 1 unit to treat hypotension in an adult.



Septic Shock

- Exogenous vasopressin has been used in patients with septic shock in several studies. AVP infusion (0.01–0.04 U/min) increased peripheral vascular resistance and arterial blood pressure within minutes of application. No increase in pulmonary vascular resistance or pulmonary artery pressure was reported in patients treated with low-dose vasopressin (0.04 U/min), nor were cardiac complications or changes in electrolyte, blood and urine osmolality, or metabolic variables.



Shortage

Reason for the Shortage American Regent discontinued vasopressin injection in early 2015.1,2 Par Sterile Products (formerly JHP) discontinued Pitressin injection in November 2014

Par Sterile Products introduced Vasostrict injection in November 2014. This is the only FDA-approved vasopressin injection.

Fresenius Kabi will discontinue distributing vasopressin on March 15, 2015. A letter is available regarding this discontinuation.

See more at: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/bulletin.aspx?id=795#sthash.XkiyeTLH.dpuf>

Available Products Vasostrict Injection, Par Sterile Products 20 units/mL, 1 mL multi-dose vial, 25 count (NDC 42023-0164-25)

See more at: <http://www.ashp.org/menu/DrugShortages/CurrentShortages/bulletin.aspx?id=795#sthash.XkiyeTLH.dpuf>





New Pain Drugs

- Ofirmev
- Caldolor
- Sufentanil Patch
- Nucynta
- Remoxy
- Mexiletine

- Antidote: Entereg
 - (almivopam)





CDC Statement — Worst EVER?

A 'civil war' over pain medication separates the medical community

“There’s a civil war in the pain community,” said Dr. Daniel B. Carr, president of the [American Academy of Pain Medicine](#). “One group believes the primary goal of pain treatment is curtailing opioid prescribing. The other group looks at the disability, the human suffering, the expense of chronic pain.”

Public Comment



CDC's draft *Guideline for Prescribing Opioids for Chronic Pain, 2016* is now available on Regulations.gov for public comment.

(Docket #CDC-2015-0112)

September 26, 2016

The Issues With the CDC Guidelines on Opioids for Chronic Pain, According to AAPM's Director




Dr Twillman extensively emphasized the fact that these CDC guidelines are expert-based and not evidence-based. In addition, most of these experts are strongly biased, as indicated by their affiliations to, for example, anti-opioid advocacy groups.



Trollway Anesthesia

Multimodal Approach to
Acute Pain Management

Life Long Learning



Modified from Crews et al., 2002¹

1. Crews JC. *JAMA*. 2002;288:629-632. 2. World Health Organization. Pain relief ladder. <http://www.who.int>. Accessed November 21, 2011. 3. Ventafridda V, et al. *Cancer*. 1987;59:850-856. 4. ASA Task Force. *Anesthesiology*. 2004;100:1573-1581.




Life Long Learning = Better Patient Care!

We Must Start to Think Differently!

Multi-Modal Synergy Pre-emptive



SUBSYS[®]
(fentanyl sublingual spray)
100, 200, 400, 600, 800, 1200, 1600 mcg





OFIRMEV \$10.00/1000mg

- IV acetaminophen injection: Cadence Pharm
 - (Cadence was bought out) (price spike)
- Minimum dosing interval is every 4 hours
- Administer over 15 min.....well....?????
 - www.ofirmev.com
- Do not exceed max daily doses.. Adult is 4 grams per day
- Pediatric is dosed at 15mg/kg with max of 75 mg/kg/day




CHEAPPPPPPP-----Not any more... ???


- Regional Anesthesia Pain Management 2015 discusses that the purchase by Mallickrodt increased the price by 285%, costing the healthcare system nearly \$2.78 Million in inflation costs.





Figure 1 – Acetaminophen metabolism







OFIRMEV

- Liver issues is big
- Contraindicated in patients with liver failure/hepatic injury or with known hypersensitivity to acetaminophen...
- What about ETOH?
- Common side effects are: N/V; HA: insomnia; constipation, pruritus and agitation and atelectasis
- Using this drug may mask post surgical fever when used for post-operative pain.





Search keyword, molecule name, target, catalog number, or product type 

Home > Resources > Articles > COX-3: the Acetaminophen Target Finally Revealed

COX-3: the Acetaminophen Target Finally Revealed

It has been known for years that non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and acetaminophen, provide relief from fever, pain, and inflammation through their actions on cyclooxygenase (COX) enzymes.¹ Two COX enzymes, COX-1 and -2, were first identified in the early 1990's as the catalysts for an important step in prostaglandin biosynthesis.² Although both enzymes have similar functions, their temporal and spatial expression patterns are very different.³ COX-1 is constitutively expressed in many somatic cell types and is considered a "housekeeping" enzyme with roles in such processes as vascular homeostasis and gastroprotection.⁴ In contrast, COX-2 expression is primarily induced by factors such as endotoxins, cytokines, and growth factors.⁵ COX-2 is expressed at sites of inflammation and produces prostaglandins that mediate inflammatory and pain sensation responses.⁶ COX involvement in inflammation, pain, and a variety of diseases has inspired researchers to investigate the actions of NSAIDs on these enzymes. Although many advances have been made over the last 10 years in understanding the pain relief and anti-inflammatory mechanisms of aspirin, ibuprofen, and the new COX-2 inhibitors, the mechanism of acetaminophen action has remained elusive.^{7,8}

Finally, identification of a new isozyme, COX-3, suggests that it is the target for acetaminophen.⁹ COX-3 was discovered by Northern analysis of canine cerebral cortex RNA using a COX-1 cDNA probe. The COX-1 probe unexpectedly illuminated a band at 2.6 kb, labeling a transcript later confirmed to be COX-3, an alternate splice variant of COX-1 in which intron 1 is retained (Figure 1). Interestingly, intron 1 is not only present in canine, human, and murine versions of COX-3, but it is conserved in length and sequence in these species as well. While COX-3 retains all of the important catalytic and structural features of COX-1 and -2, it is likely that intron 1 is responsible for the deviant enzymatic properties of COX-3 perhaps via subtle alterations in structure, glycosylation state, and/or expression.⁹

Thus far, little is known about the temporal regulation of COX-3 expression. However, it has been known for decades that acetaminophen inhibits COX activity in canine brain






Ibuprofen-Caldolor \$10



- Think about Ketorolac.. Actions and side effects
- Big differences... Less action on Cox 1 and more Cox 2 action..
- What does this mean? Less bleeding.. More pain control can give anytime during the surgery... better now that we can give per--op
- 400mg/4ml or 800mg/8ml
- Dilute and administer over 30 minutes
- 400mg-800mg Over 30 min repeat every 6 hours PRN*
- Fluids “ well hydrated prior to use”





Alkermes Pharm—Meloxicam IV


Meloxicam IV/IM is a proprietary, Phase III-ready, long-acting COX-2 NSAID used to target moderate to severe acute pain. Meloxicam IV/IM is a nonsteroidal anti-inflammatory drug... In five phase II studies treating more than 700 patients with acute pain, meloxicam IV/IM demonstrated positive effect on treating rapid onset of pain relief and "time to peak" analgesic effect, 18 to 24 hour duration of pain relief as well as favorable tolerability.

Lots of exciting information coming about related to Meloxicam! More COX 2 than previous thought



Sufentanil \$3.52/50mcg

- 5 - 10X more potent than fentanyl
- Sufentanil 0.0035 mg = fentanyl 0.05 mg
- Safe therapeutic index: 25,211
- Dose: .025 - 30 $\mu\text{g}/\text{kg}$
- Analgesic dose: 0.1 - 0.4 $\mu\text{g}/\text{kg}$ IV
- Maintenance dose: 1 $\mu\text{g}/\text{kg}$ followed by 0.25-0.5 $\mu\text{g}/\text{kg}/\text{hr}$
- High dose: 10 - 30 $\mu\text{g}/\text{kg}$



- **New PATCH coming out from Durrect Pharm....**



Sufentanil 30 mg tablet



Sufentanil tablets dispensed sublingually with a handheld PCA device (15mcg) or via single-dose applicator (30mcg) from a healthcare professional are in late-stage development for treatment moderate to severe acute pain.

When administered sublingually, sufentanil's fast onset of analgesia, noninvasive route of delivery and favorable patient satisfaction ratings make it a potential alternative to IM or IV dosing.

The type and frequency of adverse events observed in the studies were typical of opioids in a post-operative setting with reports of nausea, vomiting and somnolence more common in the active drug cohorts.

2017, Neil Singla, Harold Minkowitz, Tong-Joo Gan, Yu-kun Chiang, Karen DiDonato, Pamela Palmer



ARX-04
HCP Administered
Single 30mcg dose
Sufentanil Tablet



Investigating Moderate to Severe acute pain treatment in medically supervised settings





DSUVIA-Sublingual Sufentanil

DSUVIA

Treatment for **Pain**

AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA in the United States, for the Treatment of Moderate-to-Severe Acute Pain

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate to severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg), known as ARX-04 outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, was recently submitted to the FDA for review.





Fentanyl Patch

- Transdermal Patch
- Technology changing for delivery
- **On Demand? : Fentanyl iontophoretic transdermal system provides a 40 mcg dose of fentanyl per activation on-demand**
- Other fentanyl thoughts:
 -
 - BUCCAL TABLET; BUCCAL SOLUBLE FILM; SUBLINGUAL NASAL SPRAY; SUBLINGUAL SPRAY





Life Long Learning = Better Patient Care!

Transdermal Anesthesia



INSYS

THERAPEUTICS, INC.

SUBSYS[®]

(fentanyl sublingual spray)
100, 200, 400, 600, 800, 1200, 1600 mcg

www.subsyspray.com

Actiq[®]

(fentanyl citrate) oral transmucosal lozenge



Figure 2.



ed
ered

consultant




Zhonghua Yi Xue Za Zhi. 2017 Jan 24;97(4):295-299. doi: 10.3760/cma.j.issn.0378-2491.2017.04.012.

[Effect of dexmedetomidine alone for postoperative analgesia after laparoscopic cholecystectomy].

[Article in Chinese; Abstract available in Chinese from the publisher]

Chen XH¹, Wang ZJ, Xiang QM, Zheng JW.

Alpha 2 Agonists Pathways



Recro Pharm Dex-IN

Recro's Dex-IN, an intranasal form of dexmedetomidine, which has been tested as an analgesic drug for post-operative pain. Last year the company's lead drug passed a Phase Ib trial that demonstrated its proof of concept in providing effective pain relief. However, in September **Recro Pharma** halted a trial of its lead product candidate Dex-IN.

The company decided to stop the trial because it does not believe the study would achieve "statistical significance" in its current design. **Recro Pharma** has an upcoming interim analysis of ongoing Post Op Day 1 Phase II trial for Dex-IN, and depending on clinical success, the possibility for two proprietary compounds to enter Phase III by year end.





Trollway & Anesthesia Gabapentin

Life Long Learning =



ONCE-DAILY
Gralise[®]
(gabapentin) tablets

- Gabapentin is typically well tolerated in the correct doses:
- Doses range 300-1200 mg single doses for anesthesia : max dose is 1200mg TID or max of 3600mg/day
- Higher the dose (smaller the patient) more side effects (keep in mind excretion i.e. renal failure)
- Typically:
 - Somnolence
 - Dizziness
 - Fatigue
 - Impaired concentration
- Typically single small doses (300-600) little problems
- Keep in mind Half life of 5-7 hrs



Format: Abstract

Send to

[J Pain Res. 2016 Sep 12;9:201-10. doi: 10.2147/JPR.S112025. eCollection 2016.](#)

Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis.

[Amuzam S¹](#), [Lau CS²](#), [Chamberlain RR³](#).

Author information

Abstract

OBJECTIVE: Effective postoperative pain management is crucial in the care of surgical patients. Opioids, which are commonly used in managing postoperative pain, have a potential for tolerance and addiction, along with sedating side effects. Gabapentin's use as a multimodal analgesic regimen to treat neuropathic pain has been documented as having favorable side effects. This meta-analysis examined the use of preoperative gabapentin and its impact on postoperative opioid consumption.

MAIN RESULTS AND METHODS: A comprehensive literature search was conducted to identify randomized control trials that evaluated preoperative gabapentin on postoperative opioid consumption. The outcomes of interest were cumulative opioid consumption following the surgery and the incidence of vomiting, somnolence, and nausea.

RESULTS: A total of 1,793 patients involved in 17 randomized control trials formed the final analysis for this study. Postoperative opioid consumption was reduced when using gabapentin within the initial 24 hours following surgery (standard mean difference: -1.25, 95% confidence interval [CI], -1.56 to -0.73, $P < 0.001$). There was a significant reduction in morphine, fentanyl, and tramadol consumption ($P < 0.05$). While a significant increase in postoperative somnolence incidence was observed (relative risk 1.30, 95% CI 1.10-1.54, $P < 0.001$), there were no significant effects on postoperative vomiting and nausea.

CONCLUSION: The administration of preoperative gabapentin reduced the consumption of opioids during the initial 24 hours following surgery. The reduction in postoperative opioids with preoperative gabapentin increased postoperative somnolence, but no significant differences were observed in nausea and vomiting incidences. The results from this study demonstrate that gabapentin is more beneficial in mastectomy and spinal, abdominal, and thyroid surgeries. Gabapentin is an effective analgesic adjunct, and clinicians should consider its use in multimodal treatment plans among patients undergoing elective surgery.

Full text links

[Full text via CrossRef](#)

Save items

Similar articles

- [Review](#) Preemptive use of gabapentin in abdominal hysterectomy. [Gynecol Gynaecol. 2014]
- Preoperative gabapentin for postoperative analgesia: a meta-analysis. [Can J Anaesth. 2006]
- Analgesic effects of gabapentin after analgesic surgery in children: a rat. [Paediatr Anaesth. 2014]
- Gabapentin and postoperative pain: a qualitative and quantitative systematic review. [DMC Anesthesiol. 2007]
- [Review](#) Perioperative dexmedetomidine for acute pain. [Oxidative Medicine Syst Rev. 2016]

See reviews...

See all...

Related information

References for this PMC Article



Gabapentin not just for pain!

Format: Abstract -

Effects of a single 1200-mg preoperative dose of gabapentin on anxiety and memory.

Author information

Abstract

BACKGROUND: Gabapentin has anticonvulsant and antiepileptic effects. We therefore evaluated the effects of gabapentin administration on anxiety, amnesia, and cognition. We tested the primary hypothesis that 1200 mg of oral gabapentin 2 to 3 h before surgery reduces preoperative anxiety. Our secondary hypothesis was that gabapentin administration is sedative without causing preoperative amnesia.

STUDY DESIGN: Prospective, randomized, and placebo-controlled study.

METHODS: Surgical patients having general anesthesia were randomly assigned to either 1200 mg oral gabapentin ($n=32$) or an identical looking placebo ($n=32$) 2 to 3 h before anesthesia. Anxiety, cognition, and amnesia were evaluated before anesthesia, 2 h thereafter, and postoperatively. Postoperative anxiety was measured using the Spielberger state-trait anxiety inventory (STAI state), and the visual analogue scale anxiety (VAS). Memory was assessed with the picture recall test of Goodglass and Vanderwart. Results were compared with Mann-Whitney U, or Chi-Square test as appropriate. $P<0.05$ was considered statistically significant.

RESULTS: STAI state, our primary outcome, increased significantly in the gabapentin group from 37.2 to 39.0 and remained unchanged in the placebo group from 39.3 to 37.9 ($P=0.003$). The VAS score for anxiety also increased, but not significantly, from 28.2 to 35.3 in the gabapentin group and from 28.7 to 24.7 in the placebo group ($P=0.055$). No difference was observed in the amnesia effect, nor did the groups differ in terms of recovery times or sedation scores.

CONCLUSION: Gabapentin premedication, 1200 mg, provides preoperative analgesia without causing sedation or language preoperative memory.

Copyright © 2012 SAGE Publications. All rights reserved.

PMID: 22779322 DOI: 10.1177/0885066612268224

Published online on SAGE Full Text

Publication types, MeSH terms, Substances

Send to -

Full text links

Save items

Similar articles

Collected information






Microcron Technology Drugs---IROKO Pharm

ZORVOLEX is the first low dose FDA-approved NSAID developed using proprietary SoluMatrix Fine Particle Technology™.

ZORVOLEX contains diclofenac as submicron particles that are approximately 20 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution.

ZORVOLEX was developed to align with recommendations from FDA and other professional medical organizations that NSAIDs be used at the lowest effective dose for the shortest possible duration consistent with individual patient treatment goals. For more information, visit www.zorvolex.com.





Trollway Anesthesia Dyloject (Diclofenac)

LAKE FOREST, Ill., Dec. 30, 2014 /PRNewswire/ -- [Hospira, Inc.](#) (NYSE: [HSP](#)), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration (FDA) for Dyloject™ (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. Dyloject is indicated for use in adults for the management of mild to moderate pain and for the management of moderate to severe pain alone or in combination with opioid analgesics.

“While not a replacement for opioids, Dyloject is [an] injectable therapy option that can be administered more conveniently in a small-volume, intravenous bolus over 15 seconds as opposed to other injectable non-opioid analgesics that are formulated in large volumes or require dilution prior to administration and typically require an infusion of 15 to 30 minutes to administer the full dose.”



DYLOJECT

Trollway Anesthesia

Tramadol (1-3 mg/kg) Single Pre-Operative Dose

NCBI will be testing type in public web servers from 8:00 AM to 12:00 PM EDT (12:00-15:00 UTC) on Monday, September 26. You may experience problems with NCBI web sites during that time. Please plan accordingly. [Read more.](#)

Form: Abstract

Full Text Provided by NCBI

Comparison of analgesic effect of tramadol alone and a combination of tramadol and paracetamol in day-case laparoscopic surgery.

Abstract

OBJECTIVE: To compare the analgesic efficacy of tramadol alone (1.5 mg/kg, I.V.) with a tramadol (1 mg/kg, I.V.) and paracetamol combination in day case laparoscopic patients.

METHODS: The analgesic efficacy of intravenous tramadol alone (1.5 mg/kg, I.V.) (group T) was compared with a combination of intravenous tramadol (1 mg/kg, I.V.) and paracetamol 1 g (group TP) in 60 day-case laparoscopic patients in a prospective randomized double-blind trial in a tertiary care hospital. Intraoperative haemodynamic responses and postoperative vital analgesic scores were recorded across the analgesic effect.

RESULTS: Only one patient in group T received a single dose of rescue analgesia intraoperatively. The highest pain scores were recorded at 120 min postoperatively in both groups, and rescue analgesia was needed in eight patients in group T and in 12 patients in group TP ($P = 0.35$). The incidence of vomiting, nausea and drowsiness was higher in group T ($P = 0.001$).

CONCLUSION: We conclude that reducing the dose of tramadol to 1 mg/kg, I.V. and combining it with paracetamol 1 g orally decreased the incidence of side effects of tramadol without reducing analgesic efficacy.

Publication Types: Mesh Terms: Substances





Tramadol Infusion for Postthoracotomy Pain Relief: A Placebo-Controlled Comparison with Epidural Morphine

Bloch, Mark B. FGA (SA)*; Dyer, Robert A. FGA (SA)*; Hejke, Sylvia A. FGA (SA)*; James, Michael E. PhD†

Anesthesiology & Analgesia

March 2002 - Volume 94 - Issue 3 - pp 523-526

doi: 10.1097/00000539-200203000-00009

Cardiovascular Anesthesia: Research Report

J Neurosci Rural Pract. 2017 Jan-Mar;8(1):55-59. doi: 10.4103/0978-3147.195535.

Epidural tramadol via intraoperatively placed catheter as a standalone analgesic after spinal fusion procedure: An analysis of efficacy and cost.

Jangovan V, Vyakaran I¹, Linnasekaran I², Devikala I²

Anesth Pain Med. 2016 Jul 26;6(5):e37778. eCollection 2016.

Combined Ketamine-Tramadol Subcutaneous Wound Infiltration for Multimodal Postoperative Analgesia: A Double-Blinded, Randomized Controlled Trial after Renal Surgery.

Khajavi MR¹, Navardi M¹, Shariat Moharari R¹, Pourfakhr P¹, Khalili N², Etezadi F¹, Imani F¹.



Capsaicin (Zostrix)

- Is a new Receptor Born? **TRPV 1**
- Selectively stimulates unmyelinated C fibers afferent neurons and cause release of substance P
- This continued release leads to depletion of substance P and decrease in pain
- Patch and PO
- PO is chili-peppers or Herbal 40,000 H.U.
- PO is also in pure form under trials
- Could be a benefit? Heart burn? Burning sensation?





Trollway Anesthesia The Patch!

Life Long Learning = Better Patient Care!

Clonidine produces a dose-dependent impairment of baroreflex-mediated thermoregulatory responses to positive end-expiratory pressure in anaesthetized humans



Clonidine was clinically evaluated to suppress postoperative shivering in 60 patients who had undergone anesthesia for general, thoracic and vascular surgery. The study was carried out in double blind conditions with comparison of two doses (75 and 150 micrograms) of clonidine.

D3forME (Vitamin D3)

Catapres (clonidine)

Transderm (scopolamine)

Nicoderm (nicotine)

Exelon (rivastigmine) possible muscle relaxant interaction ###

Lidoderm (lidocaine)

Duragesis (fentanyl)

Fortesta, Axiron (testosterone)

Nitrodur (nitroglycerin)

Combipatch (estradiol, norethindrone) ? procoagulant

Alora, Menostar, Vivelle-dot, Estraderm (estradiol) ? procoagulant

Butrans (Buprenorphine) antagonizes opioids (mixed agonist/antagonist). Remove 4 days before surgery if need for significant doses of opioids postop

Emsam (selegiline = MAOI drug!) for severe depression or Parkinson's, may need to continue as long as providers



Trollwa



Exelon®



A Drug used for the treatment of Alzheimer's and is a cholinesterase inhibitor. Complete action is unknown!

Rivastigmine, an acetyl cholinesterase inhibitor, may be administered orally or as a transdermal patch for treatment of Alzheimer's disease and may interfere with neuromuscular blocking drugs.

Antibiotics

Renal Failure

Liver Failure

Temperature, Ph

Dibucaine Number

•FDA approves the first treatment for dementia of Parkinson's disease. FDA News Release. U.S. Food and Drug Administration. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108680.htm> Accessed October 16, 2013.

•Jeffrey S. FDA approves Exelon Patch for severe Alzheimer's. Available at: <http://www.medscape.com/viewarticle/807062> Accessed October 16, 2013.

•Baruah J, Easby J, Kessell G. Effects of acetyl cholinesterase inhibitor therapy for Alzheimer's disease on neuromuscular block. *Br J Anaesth* 2008;100:420.






Life Long Learning

Many "Nanomedicines" are already in routine clinical use

Trollway & Anesthesia Nanoparticles:



Recent article:

Nano anesthesia: A Novel, Intravenous Approach to Ankle Block in the Rat by Magnet-Directed Concentration of Ropivacaine-Associated Nanoparticles

Anesthesia and Analgesia: April 2014





Exparel

- EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam[®]. A single intraoperative injection given at the close of surgery delivers postsurgical pain control with reduced opioid requirements for up to 72 hours
 - Following its release from the DepoFoam[®] particles, the rate of systemic absorption of bupivacaine is dependent upon the total dose of drug administered, the route of administration, and the vascularity of the administration site
- a pivotal soft tissue trial of EXPAREL versus placebo, patients experienced a 30% reduction in cumulative pain scores and a 45% reduction in opioid consumption





DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Silver Spring, MD 20901

TRANSMITTED BY FACSIMILE

Dave Stack
President and CEO
Pacira Pharmaceuticals, Inc.
5 Sylvan Way
Parsippany NJ 07054

RE: NDA # 022496
EXPAREL® (bupivacaine liposome injectable suspension)
MA# 68

WARNING LETTER

Dear Mr. Stack:

As part of its routine monitoring and surveillance program, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed educational technique flashcards (EXP-AP-0124-201209 & EXP-AP-0134-201210) (administration guides) and a journal ad (EXP-AP-0089-201302) for EXPAREL® (bupivacaine liposome injectable suspension) (Exparel) submitted by Pacira Pharmaceuticals, Inc. (Pacira) under cover of Form FDA-2253. The journal ad was also submitted as a complaint to the OPDP Bad Ad Program. The administration guides provide evidence that Exparel is intended for new uses for which it lacks approval, and for which its labeling does not provide adequate directions for use, which renders Exparel misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and make its distribution violative. See 21 U.S.C. 355(a), 352(f); 331(a), (c), 21 CFR 201.5; 201.100; 201.115; 201.128. In addition, the journal ad is false or misleading because it omits the following information: The information



Search our site... 🔍

- AANA ▾
- MY AANA ▾
- MY CE ▾

- About Us
- Articles
- Meetings
- CE & Education
- Insurance
- Advocacy
- News & Journal
- Insurance
- Patients

- AANA Journal
- Legal Briefs
- Periodicals
- News
- Advertising & Sponsorship
- Media
- In Memoriam
- National CRNA Week
- Current Events
- Convention Daily

[AANA](#) / [News & Journal](#) / News

Potential for Wrong Route Errors with Exparel

There is a dangerous potential for errors in the administration of two "look-alike" medications that are or will be common in anesthesia practice in this country: propofol and the new bupivacaine liposomal suspension Exparel, *not meant for IV administration*. Both are milky white suspensions, and because propofol has been the only such medication for many years, a real potential for error exists.

Exparel is a local anesthetic that is infiltrated into a surgical wound during a surgical procedure to produce postoperative analgesia. It is not intended for systemic use. When prepared in syringes, these products essentially look identical. If Exparel is accidentally administered intravenously instead of propofol, *toxic blood concentrations might result, and cardiac conductivity and excitability may be depressed, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.*

Propofol is used as an anesthetic during surgical procedures and as a sedative during procedures or for patients undergoing mechanical ventilation. Thus, Exparel and propofol may be used in similar healthcare settings.

<http://www.aana.com>



Life Long Learning = Be



Trollway Anesthesia Exparel



**Certified
Registered
Nurse
Anesthetist**



Posidur

- New product just like Exparel
- Except Clear.... Could this be trouble?





Trollway Anesthesia Lipid Rescue



LipidRescue™

TREATMENT FOR LOCAL ANESTHETIC-INDUCED CARDIAC ARREST

PLEASE KEEP THIS PROTOCOL ATTACHED TO
THE INTRALIPID BAG

In the event of local anesthetic-induced cardiac arrest that is unresponsive to standard therapy, an additive to standard cardiopulmonary resuscitation, Intralipid 20% should be given to the following dose regimen:

- Initially 20% 1.5ml/kg over 1 minute
- Follow immediately with an infusion at a rate of 0.25 ml/kg/min.
- Continue until compressions (spontaneous circulation)
- Repeat bolus every 1-2 minutes up to 3 mL/kg total dose until circulation is restored.
- Continue infusion until hemodynamic stability is achieved, because the role for 0.25 ml/kg/min EPP is unclear.
- A maximum total dose of 3ml/kg is recommended.

In practice, it is recommended to add 10ml

- Take a 10ml bag of Intralipid 20% and draw 10ml
- Draw up 10ml of glucose 5%, 10%
- Also attach the intralipid bag to an IV administration set (bypassed) and run it IV over the next 10 minutes
- Repeat the bolus up to three more – if spontaneous circulation has not returned.

If you use Intralipid to treat a case of local anesthetic toxicity, please report it at www.lipidrescue.org. Remember to relock the lipids. We 7/06

- 20% lipid solution
- 1.5 ml/kg over 1 minute
- Follow immediately by a infusion at rate of 0.25ml/kg/min (17.5 ml/min for a 70 kg adult)
- Repeat dose if no improvement – and double the infusion rate
- Max of 10 ml/kg???
- www.lipidrescue.org
- ACLS-----limit epi----Weinberg work!
- What about Propofol? (Propofol is 1%)





Life Long Learning = Better Patient Care!

Trollway Anesthesia Other Things to Remember!

- Ask the question.... What about other treatments?
- What did Larry Say?



Nurse
Anesthetist



The Saving Grace!

- Wellbutrin 7.95 gms, Lamotrigine 4 grams
- Wellbutrin 100mg/TID
- Lamotrigine 300mg/QD





Life Long Learning = Better Patient Care!

Trollway Anesthesia

Many classes of compounds bind and inhibit Na channels

- Local anesthetics
 - General anesthetics
 - Ca channel blockers
 - α_2 agonists
 - Tricyclic antidepressants
 - Substance P antagonists
 - Many nerve toxins
- Benadryl

Droperidol ????

"LIPID RESCUE" FOR TRICYCLIC ANTIDEPRESSANT CARDIOTOXICITY

Michael Stephen Blaber, *mrcs,** Jamal Nasir Khan, *mrcr,*† Judith Anne Brebner, *mrcp,*‡ and Rachel McColm, *mrcp*§

*Department of Cardiology, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK, †Department of Cardiology, University Hospital of North Staffordshire, Newcastle, Stoke-on-Trent, UK, ‡Department of Respiratory Medicine, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK, and §Department of Emergency Medicine, Hereford Hospitals NHS Trust, County Hospital, Hereford, UK

Reprint Address: Jamal Nasir Khan, *mrcr,* Department of Cardiology, City General Hospital, University Hospital of North Staffordshire, Newcastle Road, Stoke-on-Trent ST4 7QP, UK

CAUTION NEEDED?
Droperidol's risks may seem low, but some resist removing its warning.



Mod Lett Drugs Ther. 1968 Nov 20;10(24):99-100.

Innovar injection--a combination of droperidol and fentanyl.

[No authors listed]



Life Long Learning = Better Patient Care!

Harvey M, Cave G. Case report: successful lipid resuscitation in multi-drug overdose with predominant tricyclic antidepressant toxidrome. *Int J Emerg Med.* 2012 Feb 2;5(1):8. [Epub ahead of print]

Blaber MS, Khan JN, Brebner JA, McColm R.J "Lipid Rescue" for Tricyclic Antidepressant Cardiotoxicity. *Emerg Med.* 2012 Jan 11. [Epub ahead of print]

Jakkala-Saibaba R, Morgan PG, Morton GL. Treatment of cocaine overdose with lipid emulsion. *Anaesthesia.* 2011 Dec;66(12):1168-70. doi: 10.1111/j.1365-2044.2011.06895.x.

Liang CW, Diamond SJ, Hagg DS. Lipid rescue of massive verapamil overdose: a case report. *J Med Case Reports.* 2011 Aug 20;5(1):399


Jovic-Stosic J, Gligic B, Putic V, Brajkovic G, Spasic R. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. *Clin Toxicol (Phila).* 2011 Jun;49(5):426-30.

Shih YH, Chen CH, Wang YM, Liu K. Successful reversal of bupivacaine and lidocaine-induced severe junctional bradycardia by lipid emulsion following infraclavicular brachial plexus block in a uremic patient. *Acta Anaesthesiol Taiwan.* 2011 Jun;49(2):72-4.





Alvimopan (Entereg)



Alvimopan

- μ -Opioid antagonist that is restricted from crossing the blood-brain barrier
- Blocks peripheral gastrointestinal side effects (eg, ileus, constipation) without compromising CNS activity
- Oral dosing
 - Low systemic absorption
 - High μ -receptor affinity
 - Appropriate for patients with chronic pain

CNS, central nervous system.
Schmidt WK. Am J Surg. 2001;192(SA suppl):275-380.



Mivacurium is coming back...

The screenshot shows a web browser displaying a market research report. The page title is "2016 Mivacurium (CAS 105791-40-6) Industry Market Report". The report details include:

Lowest Price Guaranteed	Length	Publisher	Publisher Date	QID
from \$2,900	150 Pages	Prof-Research	August 30, 2016	FR0P15093565

Additional information at the bottom of the report preview includes:


- PDF E-mail From Publisher
- \$2,500
- Purchase
- Research assistance





Gantacurium

Phase 2 complete



- Is this a new Generation being born of NMB?
- Based on amino acid pathway—olefinic
- This drug is chemically degraded by rapid adduction to L-cysteine and removes Chlorine
- These two routes make it unavailable to bind to acetylcholine receptor
- Does not require Liver, Kidneys, Temperature or pH
- Two exciting analogs...
- There has always been a search for the new Suxx.....



Gantacurium

- Dose: 0.5 mg/kg
- Fast acting with short duration
- Exciting new group of drugs!
- Key is: NO histamine release!



CW002

- Same pathway as Gantacurium!
- This compound Lacks Chlorine
- Dose: 0.15mg/kg
- Fast acting Intermediate duration
- Key is: NO histamine release!





CW 011

- This is the baby of this group...
- Lacks Chloride so slower to break down
- Dose: 0.10 mg/kg
- Fast acting more intermediate duration
- Key is: NO histamine release!





L-Cysteine

Dissolved in concentration of 200mg/ml

- Antidote for New class of Muscle relaxants
 - Olefinic isoquinolone Diester NMB
 - Only works with new group of NMB's





Cysteine

Human Studies: IV administration of exogenous L-Cysteine induced faster recovery.

Dose in Studies: 5-50mg/kg

- (average dose is 10mg/kg)

Compared to Edrophonium reversal with atropine.

Did not need to give antimuscarinics agent.

Reversed in 1 minute

There are risks...High doses: (added to TPN) but 1-1.5 grams/kg can cause neuro defects reported in infants



FDA News Release

FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery

First drug approved in new class of medications

[SHARE](#) [TWEET](#) [LINKEDIN](#) [PRINT](#) [EMAIL](#) [PRINT](#)

For Immediate Release

December 15, 2015

Release

The U.S. Food and Drug Administration today approved Lidion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.

Rocuronium bromide and vecuronium bromide are neuromuscular blocking drugs that cause temporary paralysis by interfering with the transmission of nerve impulses to the muscle and are used to paralyze the vocal cords when patients require an artificial airway or breathing tube for surgery, a process called tracheal intubation. They can also be used to prevent patients from moving during surgery while they are receiving general anesthesia. Neuromuscular blocking drugs are also sometimes used to prevent the body from breathing automatically when a patient has to be placed on a ventilator.

"Lidion provides a new treatment option that may help patients recover sooner from medications used for intubation or ventilation during surgery," said Sharon Herz, M.D., director of the Division of Anesthesia, Analgesia and Addiction Products in the

Inquiries

Media

For more information:
[301.796.0903](tel:3017960903)
[240.402.4177](tel:2404024177)

Consumers

888.LIFE.FDA

Related Information

- FDA Approved Drug: [Diazepam and Anexes](#)
- FDA Drug Information

Follow FDA

- Follow @FDA 1114
- Follow FDA
- Follow @FDAinfo




The Official Journal of the Anesthesia Patient Safety Foundation
apsf NEWSLETTER February 2016

- Articles:
- [Monitoring of Neuromuscular Blockade](#)
- [Trends in Anesthesia Practice Management Groups](#)
- [Expanding Our Influence](#)
- [Providing Support](#)
- [Safety of Neuromuscular Blockade](#)
- [Trends of Sugammadex](#)
- [Emergency Market Withdrawal](#)
- [FDA Issues First Safety Communication](#)
- [NMD Reversal and Outcomes](#)
- [USA/UK Ties: Failure](#)
- [Dear SIR: Increased Network Connection](#)
- Announcements:
- [Grow the Data](#)
- [March Support of APSF](#)
- [NBCRNA Support of APSF](#)
- [Medicare Support of APSF](#)
- [APSF DOTE](#)

The Development and Regulatory History of Sugammadex in the United States

by Glenn Murphy, MD

The Neuromuscular Research Group at Carleton Neurology Scotland (now at Glasgow) had been working on the development of fast-onset, short-acting nondepolarizing steroidal neuromuscular blocking agents since the 1960s, which led to the development of pancuronium, vecuronium and rocuronium. Shortly after the launch of rocuronium, questions arose about a possible action of rocuronium on smooth muscle neurotransmission, so Dr. Anton Rom



Space-filling model of sugammadex molecule


Photo courtesy of Dr. Anton Rom

was conducting Dr. Rom was performing smooth muscle studies at the same research site. Rocuronium is not very water soluble, so buffer antititers with a pH of 4 are required. Dr. Rom attempted to dissolve rocuronium in organic solvents that were traditionally used for smooth muscle studies, none of which were able to solubilize rocuronium. Next, he decided to examine cyclodextrins, which were demonstrated to dissolve steroidal hormones. Cyclodextrins are rigid, ring-shaped molecules composed of sugar units. The outside of the cyclodextrin is hydrophilic, which makes the molecule water soluble. The hole in the middle of the cyclodextrin ring is hydrophobic, which allows lipophilic molecules, like steroids, to enter this cavity, creating water soluble complexes.


Since rocuronium has a steroidal nucleus, Dr. Rom speculated that rocuronium would form complexes with cyclodextrins. This binding would prevent rocuronium from acting on the nicotinic acetylcholine receptor and allow rapid reversal of neuromuscular



CYCLODEXTRINS



Cyclodextrins are poly saccharide compounds that were analyzed as scavenging molecules for toxins and additives for food materials






Beta Cyclodextrins were developed as vehicles for long acting drugs

They have been tried as solubilizing agents for various drugs like


Propofol, bupivacaine, sufentanil



Trollway & Anesthesia Sugammadex--Bridion



- Forms a very tight water soluble complex with steroidal NDMR
- i.e. ROC > VEC > PANC
- It is biologically inactive, does not bind to plasma proteins
- Does not rely on renal excretion
- WE have always mis-used muscle relaxants (first reported 1979)
- IV administration results in rapid removal of free drug from the plasma. This action creates a concentration gradient favoring the movement of the NDMR molecules from the NMJ back into the plasma, where they are encapsulated by free Sugammadex molecules.



- Does not affect SUXX or benzyloquinoliniums;
- If after using Sugammadex and paralysis needs to be achieved consider using these drugs
- SIDE EFFECTS: hypotension; coughing (was from a study when given to awake patients) vomiting, nausea, dry mouth, decreased temperature
- Is traditional Neuromuscular function monitoring needed?



Cost of Sugammadex

- 2mg/kg dose: 140mg, one 2mL vial = \$84.93
- 4mg/kg dose: 280mg, one 5mL vial = \$155.55
- 16mg/kg dose: 1120mg, two 5mL vials and one 2mL vial = \$396.03
- Caveats
 - Uncontracted prices from distributor
 - Patient cost usually approximately 3x this cost

Dose examples: ROC 1.2mg.kg administered and three minutes later 16mg/kg of Sugammadex given, this provides faster onset/offset profile than suxx

Will this change the face of anesthesia??






Fig. 5. (A) Current Radiograph crystal structure of a rocuronium molecule and a sugammadex molecule. (B) Synopsis encapsulation of rocuronium molecule (*blue*) by a sugammadex molecule (*green*) at 1:1 ratio. (From Cameron KS, Clark JK, Cooper A, et al. Modified gamma-cyclodextrins and their rocuronium complexes. *Org Lett* 2002;4:3403–6 ©American Chemical Society; with permission.)



Sugammadex - FDA Saga

- 2014 Lit review identified 15 cases of hypersensitivity reactions from sugammadex.

- All within 5 minutes of administration.

- Most common reactions rash and anaphylaxis.

- 11 patients skin tested, 10 positive



Use of Sugammadex

• Binds Roc > Vec >> Panc

• Dose Depends on Depth – Single Bolus

• If 2 TOF twitches returned, **2mg/kg**

• If 1-2 PTC and 0 TOF twitches, **4mg/kg**


• If reversal needed as soon as 3 mins after 1.2mg/kg rocuronium dose, **16mg/kg**

• Confirm reversal

• Time = 1.5-3 minutes (mean)



::



If 2nd twitch of DBS or at least 2nd twitch of TOF count is present: Dose = 2mg/kg

If any other response from nerve stimulation: Dose = 4mg/kg

For emergency use or no response from working nerve stimulator: Dose = 16mg/kg

Sugammadex – Adverse Reactions

- Serious but rare:
 - Anaphylaxis
 - Bradycardia
- > 10%
 - Nausea, Vomiting, Pain, Hypotension, Headache
- Signs of emergence (moving, sucking, chewing)
- Large meta-analysis with > 1500 patients = no significant difference in side effects compared with neostigmine with less residual paralysis





Trolley Anesthesia

In response to the FDA's requests, 4 additional studies were conducted examining the impact of sugammadex on coagulation. These investigations demonstrated a small increase in PT and aPTT that occurred within minutes of administration, but resolved within an hour.

In addition, in a large study of patients undergoing hip or knee replacement surgery, no increase in bleeding or transfusion requirements was observed in patients randomized to receive sugammadex





Sugammadex - Bleeding

- Increases PTT, PT/INR up to 25% for up to 1h in healthy volunteers
- In a study of patients with major lower extremity orthopedics surgery, PTT and PT/INR increases < 10% were noted (**did NOT require transfusion**)
- No difference in bleeding, anemia incidence
- Concomitant thromboprophylaxis in this study






Cardiac

In order to address concerns related to cardiac arrhythmias, an analysis of phase 2 and 3 clinical studies was conducted, as well as an analysis of post-marketing data.

These study findings indicated that QTc was not prolonged in patients given sugammadex. The studies also indicated that arrhythmias did not occur with greater frequency with sugammadex compared to neostigmine, although bradycardia can occur with both agents.





Sugammadex – Not For Use In

- Children < 18
 - Some rat studies show possible decreased bone development in childhood
- Severe renal impairment (renal excretion)
 - GFR < 30
- Elderly patients exhibit slower recovery





Sugammadex - Bleeding

- Increases PTT, PT/INR up to 25% for up to 1h in healthy volunteers
- In a study of patients with major lower extremity orthopedics surgery, PTT and PT/INR increases < 10% were noted
- No difference in bleeding, anemia incidence
- Concomitant thromboprophylaxis in this study



Sugammadex – Drug Interactions

- Toremifene (SERM) may prolong NMBD recovery
- Other drugs could displace rocuronium
- Physically incompatible with: ondansetron, ranitidine, verapamil



FDA Warns!

FDA also warned about the potential for marked bradycardia, and that some of these cases have resulted in cardiac arrest, often within minutes of giving the drug.

Patients should be closely monitored for hemodynamic changes during and after reversal of neuromuscular blockade, and physicians should give anticholinergic agents, such as atropine, if they observe clinically significant bradycardia, the agency said.

Physicians should also advise women using hormonal contraceptives that the drug may temporarily reduce contraceptive efficacy, so they should use an alternative method of birth control for a period of time after getting the drug.

The most common adverse reactions with sugammadex included vomiting, hypotension, pain, headache, and nausea.





Recurarization Bottom Line

- (Except in magnesium case) No clinically significant recurarization has been reported when sugammadex is used as labeled according to manufacturer recommendations
- Recurarization can be seen if an inadequate dose is used!!





Package insert

7.3 Interaction Potentially Affecting the Efficacy of Hormonal Contraceptives

In vitro binding studies indicate that BRIDION may bind to progestogen, thereby decreasing progestogen exposure. Therefore, the administration of a bolus dose of BRIDION is considered to be equivalent to missing dose(s) of oral contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day that BRIDION is administered, the patient must use an additional, non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days.

In case of non-oral hormonal contraceptives, the patient must use an additional, non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days.



Always Aware


Sugammadex and Hormonal Birth Control Interaction: Identifying and Educating Affected Patients Automatically through Health Link

Sugammadex is a medication indicated for the rapid reversal of neuromuscular blockade induced by rocuronium and Vecuronium. It was recently added to the formulary and is restricted to use in the OR and ED. Sugammadex interacts with hormonal birth control, both oral and non-oral formulations, possibly resulting in temporary loss of efficacy of the birth control for up to seven days.

Beginning September 13, 2016 documentation of sugammadex administration by the provider will generate an automatic educational message for women of reproductive potential who are between the ages of 10 and 60 years old. The message informs them that they received sugammadex. It also provides information about the nature of the interaction and the need for back-up birth control for seven days. Condoms and spermicides are recommended.



Sugammadex



(47 unread) - pstnbe3000 - basic rules - Bing images Preoperative Melatonin X +


anesthesiology pub. asahq.org/article.aspx?articleid=1903743

ASA Publications - Login

ANESTHESIOLOGY
The Journal of the American Society of Anesthesiologists, Inc.

Search... All Publications - Advanced Search

Home Issues ASA Practice Parameters Online First Topics Podcasts CME Info



The Resounding Mission of Anesthetic Care

View Full Size

ISSUE

Methods and Materials

Results

Discussion

References

FREE

Perioperative Medicine | July 2009

Preoperative Melatonin and Its Effects on Induction and Emergence in Children Undergoing Anesthesia and Surgery

Zeev N. Kain, M.D., M.B.A.; Jill E. MacLaren Ph.D.; Leslie Herrmann, B.S.; Linda Mayes, M.D.; Abraham Rosenbaum, M.D.; Justin Hata, M.D.; Jerrold Lerman, M.D., F.R.C.P.C., F.A.N.Z.C.A.

[+ Author Affiliations & Notes](#)

Anesthesiology 7 2009, Vol.111, 44-49.
doi:10.1097/ALN.0b013e3181a91870

RELATED ARTICLES

Sevoflurane versus Halothane: Postoperative Maladaptive Behavioral Changes: A Randomized, Controlled Trial

Family-centered Preparation for Surgery Improves Perioperative Outcomes in Children: A Randomized Controlled Trial

The Clinical Anaesthesia Viva Book, 2nd Edition.

Changes in Functional Residual Capacity and Lung Mechanics during Surgical Repair of Congenital Heart Diseases: Effects of Preoperative Pulmonary Hemodynamics



Antidote to Factor X inhibitors

Portola Pharmaceuticals (Nasdaq:[PTLA](#)) today announced that **andexanet alfa**, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, has been granted orphan drug designation by the FDA's Office of Orphan Products Development for reversing the anticoagulant effect of direct or indirect Factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery. Currently, there is no approved antidote for these patients.

Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

Trial included 123 patients taking Pradaxa who received Praxbind due to uncontrolled bleeding or because they required emergency surgery. In this ongoing trial, based on laboratory testing, the anticoagulant effect of Pradaxa was fully reversed in 89 percent of patients within four hours of receiving Praxbind. In this patient trial, the most common side effects were low potassium (hypokalemia), confusion, constipation, fever and pneumonia.







Life Long Learning = Better Patient Care!

Trolley Anesthesia? --- New Ultrasound?---

"Another tool to distinguish us from the CRNA"



The Ultrasound Probe in the Hands of the Anesthesiologist: A Powerful New Tool for Airway Management

MICHAEL SELTZ KRISTENSEN, MD

*Head of Section for Anesthesia
for ENT, Head, Neck, and Maxillofacial Surgery
Rigshospitalet, University Hospital of Copenhagen, Denmark*

WENDY H.L. TEOH, MBBS, FANZCA

*Department of Women's Anesthesia
KK Women's and Children's Hospital Singapore
Adjunct Assistant Professor, Duke University-MUS
Graduate Medical School, Singapore*





Others that might impact Anesthesia

- JM-1232 New hypnotic nonbenzo from Japan
- PF0-713 Variant of Propofol
- AZD-3043 Nonbarb hypnotic

Just FDA approved:

Idarucizumab to reverse pradaxa

Factor X concentrate




RE-VERSE AD™

Study of reversal effects of idarucizumab
in patients on active dabigatran



Mechanism of action






Can I be excused?
... my brain is full !



Trollway Anesthesia Questions

Thank you!

Email me for the articles:
pstrube3000@yahoo.com



Three forms of anesthesia.